| 0 (0%) | 06-28 18:07 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.85 | 1-year : | 7.15 |
| Resists | First : | 5.01 | Second : | 6.13 |
| Pivot price | 4.24 |
|||
| Supports | First : | 3.2 | Second : | 2.66 |
| MAs | MA(5) : | 3.73 |
MA(20) : | 4.44 |
| MA(100) : | 4.23 |
MA(250) : | 4.21 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 6.9 |
D(3) : | 5.2 |
| RSI | RSI(14): 39.9 |
|||
| 52-week | High : | 6.13 | Low : | 2 |
Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is BEARISH in short-term; and NEUTRAL in mid-long term.[ STRO ] has closed above bottom band by 22.1%. Bollinger Bands are 24.8% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 3.95 - 3.97 | 3.97 - 3.99 |
| Low: | 3.63 - 3.66 | 3.66 - 3.69 |
| Close: | 3.68 - 3.72 | 3.72 - 3.76 |
Wed, 05 May 2021
Agreement to acquire TESARO - GSK
Mon, 03 Dec 2018
Tesaro Stock Soars After Announcing Agreeing to Be Bought By Glaxosmithkline - Warrior Trading News
Mon, 03 Dec 2018
GlaxoSmithKline Makes $5.1 Billion Play for Cancer Drug Specialist Tesaro - TheStreet
Mon, 03 Dec 2018
GSK reaches agreement to acquire TESARO, an oncology focused biopharmaceutical company - GSK
Wed, 24 Oct 2018
TESARO and Actress Cobie Smulders Launch Not on My Watch, a National Movement to Empower the Ovarian Cancer ... - GlobeNewswire
Wed, 28 Feb 2018
Here's Why Tesaro Inc. Stock Dipped Today - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Underperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Outperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
|
|
|
Industry:
|
|
| Shares Out | 0 (M) |
| Shares Float | 77 (M) |
| Held by Insiders | 4.86e+007 (%) |
| Held by Institutions | 0.9 (%) |
| Shares Short | 2,410 (K) |
| Shares Short P.Month | 0 (K) |
| EPS | -8.246e+007 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 0 |
| Profit Margin | -69.5 % |
| Operating Margin | 37.9 % |
| Return on Assets (ttm) | -12.8 % |
| Return on Equity (ttm) | -58.3 % |
| Qtrly Rev. Growth | 1 % |
| Gross Profit (p.s.) | 221.83 |
| Sales Per Share | 1.56867e+008 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | -1.8 % |
| Operating Cash Flow | 0 (M) |
| Levered Free Cash Flow | -112 (M) |
| PE Ratio | -0.01 |
| PEG Ratio | 0 |
| Price to Book value | 0 |
| Price to Sales | 0 |
| Price to Cash Flow | 1.48 |
| Dividend | 0 |
| Forward Dividend | 2.41e+006 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|